Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study

•We report an amended thromboprophylactic strategy using apixaban rather than low-molecular-weight heparin for high thrombotic risk myeloma patients. •No thrombotic events are reported in patients receiving prophylactic apixaban. •Major bleeding occurred in 1.2% patients on prophylactic apixaban. •Apixaban appears to be an effective and safe alternative to low-molecular-weight-heparin as thromboprophylaxis in myeloma.